Candel Therapeutics Inc
CADL6.310USD
+0.020+0.32%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
310.75MCap. mercado
PérdidaP/E TTM
Más Datos de Candel Therapeutics Inc Compañía
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Información de la empresa
Símbolo de cotizaciónCADL
Nombre de la empresaCandel Therapeutics Inc
Fecha de salida a bolsaJul 27, 2021
Director ejecutivoDr. Paul Peter Tak, M.D., Ph.D.
Número de empleados38
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección117 Kendrick Street,
CiudadNEEDHAM
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02494
Teléfono16179165445
Sitio Webhttps://www.candeltx.com/
Símbolo de cotizaciónCADL
Fecha de salida a bolsaJul 27, 2021
Director ejecutivoDr. Paul Peter Tak, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Desglose de ingresos
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 24 de may
Actualizado: sáb., 24 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.01%
Individual Investor
16.48%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.99%
Corporation
2.48%
Research Firm
0.64%
Bank and Trust
0.09%
Pension Fund
0.02%
Insurance Company
0.02%
Other
39.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
162
31.98M
60.95%
-104.17K
2025Q1
160
30.10M
67.51%
-1.81M
2024Q4
131
27.38M
62.24%
+9.09M
2024Q3
115
17.10M
48.26%
-703.44K
2024Q2
98
16.89M
49.23%
+872.97K
2024Q1
67
14.85M
50.59%
-1.40M
2023Q4
65
14.94M
51.56%
-1.48M
2023Q3
68
15.61M
53.96%
-846.00K
2023Q2
65
15.70M
54.30%
-590.47K
2023Q1
64
16.17M
55.93%
-250.07K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
7.09M
13.5%
+766.60K
+12.13%
Mar 31, 2025
Manning (Paul B.)
2.82M
5.38%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.92%
+428.26K
+19.90%
Jun 25, 2025
Baker Bros. Advisors LP
2.44M
4.64%
-544.79K
-18.27%
Mar 31, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.61%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.49%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
1.74M
3.31%
+396.95K
+29.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
3.06%
+515.63K
+47.27%
Mar 31, 2025
BKB Growth Investments LLC
1.30M
2.48%
+750.00K
+135.44%
Apr 21, 2025
Portolan Capital Management, L.L.C.
881.18K
1.68%
+127.44K
+16.91%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0.17%
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0%
Ver más
ALPS Medical Breakthroughs ETF
Proporción0.17%
Vanguard US Momentum Factor ETF
Proporción0.08%
iShares Micro-Cap ETF
Proporción0.05%
iShares Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
